PaxMedica Inc

NASDAQ:PXMDUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to neurodegenerative disorders, such as Fragile X Tremor Ataxia Syndrome (FXTAS) and post-viral Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and with rising incidence globally due to the long-term effects of SARS-CoV-2 (COVID-19). Its lead program PAX-101 is an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders fragile X syndrome (FXS), FXTAS, ME/CFS and Long COVID-19 Syndrome (LCS), a clinical diagnosis in individuals who have been previously infected with COVID-19.

Contact Information

Headquarters

303 South Broadway, Suite 125TARRYTOWN, NY, United States 10591

Phone

914-987-2876

Fax

302-636-5454

Executives

Chairman of the Board, Chief Executive Officer

Howard Weisman

Chief Financial Officer, Chief Operating Officer

Stephen Sheldon

Chief Medical Officer

David Hough

Lead Independent Director

Charles Casamento

Independent Director

John Coelho